PE20142185A1 - Pirrolidina-2-carboxamidas sustituidas - Google Patents

Pirrolidina-2-carboxamidas sustituidas

Info

Publication number
PE20142185A1
PE20142185A1 PE2014001419A PE2014001419A PE20142185A1 PE 20142185 A1 PE20142185 A1 PE 20142185A1 PE 2014001419 A PE2014001419 A PE 2014001419A PE 2014001419 A PE2014001419 A PE 2014001419A PE 20142185 A1 PE20142185 A1 PE 20142185A1
Authority
PE
Peru
Prior art keywords
chloro
phenyl
pyrrolidine
lower alkyl
substitute
Prior art date
Application number
PE2014001419A
Other languages
English (en)
Spanish (es)
Inventor
David Joseph Bartkovitz
Xin-Jie Chu
Binh Thanh Vu
Chunlin Zhao
Daniel Fishlock
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20142185A1 publication Critical patent/PE20142185A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2014001419A 2012-03-15 2013-03-12 Pirrolidina-2-carboxamidas sustituidas PE20142185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261611200P 2012-03-15 2012-03-15

Publications (1)

Publication Number Publication Date
PE20142185A1 true PE20142185A1 (es) 2014-12-29

Family

ID=47844360

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001419A PE20142185A1 (es) 2012-03-15 2013-03-12 Pirrolidina-2-carboxamidas sustituidas

Country Status (27)

Country Link
US (1) US8993614B2 (https=)
EP (1) EP2825528B1 (https=)
JP (1) JP6125546B2 (https=)
KR (1) KR20140138165A (https=)
CN (1) CN104271554B (https=)
AR (1) AR090328A1 (https=)
AU (1) AU2013203662B2 (https=)
BR (1) BR112014018959A8 (https=)
CA (1) CA2860781A1 (https=)
CL (1) CL2014001858A1 (https=)
CO (1) CO6990736A2 (https=)
CR (1) CR20140399A (https=)
DK (1) DK2825528T3 (https=)
EA (1) EA025557B1 (https=)
ES (1) ES2634290T3 (https=)
HU (1) HUE032864T2 (https=)
IL (1) IL234173A (https=)
MX (1) MX2014010942A (https=)
NZ (1) NZ626505A (https=)
PE (1) PE20142185A1 (https=)
PH (1) PH12014501542B1 (https=)
PL (1) PL2825528T3 (https=)
SG (1) SG11201404344XA (https=)
SI (1) SI2825528T1 (https=)
TW (1) TWI586648B (https=)
UA (1) UA113541C2 (https=)
WO (1) WO2013135648A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014029530A2 (pt) 2012-05-30 2017-06-27 Hoffmann La Roche compostos, composição farmacêutica e uso de um composto
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
BR112015029976A2 (pt) * 2013-06-24 2017-07-25 Hoffmann La Roche formulação farmacêutica, formulação liofilizada farmacêutica e preparações novas, métodos e usos
SG11201510816SA (en) 2013-07-03 2016-01-28 Hoffmann La Roche Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR101862955B1 (ko) * 2013-12-05 2018-05-31 에프. 호프만-라 로슈 아게 급성 골수성 백혈병(aml)을 위한 신규한 병용 치료
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
EP3131878A1 (en) * 2014-04-15 2017-02-22 F. Hoffmann-La Roche AG Solid forms of a pharmaceutically active compound
CA2946164A1 (en) * 2014-05-22 2015-11-26 The University Of Sydney Omega-3 analogues
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
CN104496822B (zh) * 2014-12-15 2016-10-26 扬州三友合成化工有限公司 一种1-氯乙基环己基丙基碳酸酯的制备方法
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN107698598B (zh) * 2016-08-08 2019-06-21 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
WO2018027477A1 (zh) * 2016-08-08 2018-02-15 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
SG11202005719UA (en) * 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
CN114230561B (zh) * 2020-09-09 2024-03-19 中国人民解放军海军军医大学 一种mdm2抑制剂类小分子化合物及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
DE69120141T2 (de) 1990-03-28 1996-11-28 Shuji Kojima Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
AU1313695A (en) 1993-12-14 1995-07-03 Sandoz Ltd. Pharmaceutical compositions containing alkyl polyoxyalkylene carboxylates
DE4435087A1 (de) 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
WO1999017120A1 (en) 1997-09-26 1999-04-08 Becton, Dickinson And Company Preparing conjugates using polyethylene glycol linkers
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
JP4317744B2 (ja) 2001-05-30 2009-08-19 ナノキャリア株式会社 高分子化合物末端への導入物結合方法
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
PT3025726T (pt) 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
MXPA06011420A (es) 2004-04-01 2007-04-20 Cardiome Pharma Corp Compuestos pegilados de modulacion de canal de iones.
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7612153B2 (en) 2004-10-25 2009-11-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) and uses thereof
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2650035C (en) 2006-04-27 2015-02-03 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
WO2008109783A2 (en) 2007-03-06 2008-09-12 The Regents Of The University Of California Detecting spin perturbations using magnetic resonance imaging
JP2008308690A (ja) 2007-06-13 2008-12-25 Bio-Cancer Treatment Internatl Ltd ポリ(エチレングリコール)機能性誘導体およびその製造方法
WO2009128789A1 (en) 2008-04-17 2009-10-22 Agency For Science, Technology And Research Vesicles for intracellular drug delivery
WO2009155431A1 (en) 2008-06-18 2009-12-23 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
PL2300514T3 (pl) 2008-07-14 2016-09-30 Sposób syntezowania zasadniczo monodyspersyjnej mieszaniny oligomerów
MX2011001887A (es) 2008-08-22 2011-04-04 Baxter Int Derivados de bencil carbonato polimericos.
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MY160424A (en) 2008-09-18 2017-03-15 Hoffmann La Roche Substituted pyrrolidine-2-carboxyamides.
WO2010151269A1 (en) 2009-06-26 2010-12-29 Biotic Laboratories, Inc. Para-xylylene based multilayer drug elution devices
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
CN101991860B (zh) 2010-11-08 2013-06-19 中国药科大学 泊洛沙姆-羧酸类药物偶联物及其制备方法与应用
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールmdm2アンタゴニスト
US8591877B2 (en) 2011-02-02 2013-11-26 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
US9212258B2 (en) 2011-02-23 2015-12-15 The Board Of Trustees Of The University Of Illinois Amphiphilic dendron-coils, micelles thereof and uses
CN102247602B (zh) 2011-06-13 2013-01-02 中山大学 一种超分子水凝胶双重药物载体及其制备方法和应用
EP2750681B1 (en) 2011-08-30 2020-05-27 Quanta Biodesign, Ltd. Branched discrete peg constructs
BR112014029530A2 (pt) * 2012-05-30 2017-06-27 Hoffmann La Roche compostos, composição farmacêutica e uso de um composto

Also Published As

Publication number Publication date
EA025557B1 (ru) 2017-01-30
SG11201404344XA (en) 2014-10-30
WO2013135648A1 (en) 2013-09-19
BR112014018959A8 (pt) 2017-07-11
PL2825528T3 (pl) 2017-09-29
PH12014501542A1 (en) 2014-09-22
JP2015512890A (ja) 2015-04-30
CL2014001858A1 (es) 2014-09-26
US8993614B2 (en) 2015-03-31
NZ626505A (en) 2016-04-29
AU2013203662A1 (en) 2013-10-03
CR20140399A (es) 2014-10-07
AU2013203662B2 (en) 2016-04-14
TW201341357A (zh) 2013-10-16
CN104271554B (zh) 2016-11-23
ES2634290T3 (es) 2017-09-27
IL234173A (en) 2017-08-31
BR112014018959A2 (https=) 2017-06-20
AR090328A1 (es) 2014-11-05
CA2860781A1 (en) 2013-09-19
EA201491623A1 (ru) 2014-12-30
UA113541C2 (xx) 2017-02-10
HUE032864T2 (en) 2017-11-28
MX2014010942A (es) 2014-11-14
KR20140138165A (ko) 2014-12-03
HK1200830A1 (en) 2015-08-14
SI2825528T1 (sl) 2017-08-31
EP2825528A1 (en) 2015-01-21
EP2825528B1 (en) 2017-05-24
US20130244958A1 (en) 2013-09-19
PH12014501542B1 (en) 2014-09-22
TWI586648B (zh) 2017-06-11
CN104271554A (zh) 2015-01-07
DK2825528T3 (en) 2017-08-14
JP6125546B2 (ja) 2017-05-10
CO6990736A2 (es) 2014-07-10

Similar Documents

Publication Publication Date Title
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20151274A1 (es) Inhibidores de erk y sus usos
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
NZ631477A (en) Substituted pyrrolidine-2-carboxamides
PE20121354A1 (es) Inhibidores del virus de la hepatitis c
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20081783A1 (es) Nuevas 2-aminooxazolinas como ligandos de taar1
PE20160432A1 (es) Compuestos utiles como inmunomoduladores
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20131377A1 (es) Triazina-oxadiazoles
PE20090772A1 (es) Derivados de bencimidazol
PE20110298A1 (es) Derivados de picolinamida como inhibidores de cinasa
PE20180177A1 (es) Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
PE20120517A1 (es) Inhibidores del virus de la hepatitis c
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20142099A1 (es) Derivados de sulfonamida
PE20040960A1 (es) Derivados de piperazina acilados como agonistas del receptor de melanocortina-4
PE20090727A1 (es) DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso

Legal Events

Date Code Title Description
FC Refusal